Page 2 - Hospital_Insights_1_2022
P. 2

The first and ONLY GLP1-RA to

        Demonstrate Primary and Secondary                                                      1.5 mg/0.5 mL


        CVD Prevention                  †,1,2,3


              ®
        † Trulicity  demonstrates primary and secondary prevention of
        major adverse cardiovascular events (MACE)* in patients
        with type 2 diabetes at cardiovascular risk. 1
        *3-component MACE in REWIND (nonfatal stroke,
        nonfatal myocardial infarction, or death).

               ®
        Trulicity  significantly reduced the risk of MACE-3 by 12% despite a majority of patients not having
        established cardiovascular disease¹


                                                                                   ADA/EASD Guideline
                                                                                   Strongest evidence for Dulaglutide
                                                                                   for primary prevention, but lacking
                                                                                   for other GLP1-RAs 2*




                                                                                   Powerful HbA1c Reduction
                                                                                         ®
                                                                                   Trulicity  proves powerful HbA1c
                                                                                   reductions of up to -1.6% across a
                                                                                   range of head-to-head clinical trials 3





                                                                                   No titration required³




                                                                                        Simple injection




                                                                                        Hidden needle  4


                                                                                        Once weekly  3



                                                                                        No mixing or
                                                                                        reconstitution
                                                                                        required 4










        ADA=American Diabetes Association; CV=cardiovascular; CVD=cardiovascular diseases; EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonists; MACE=major adverse
        cardiovascular events; MI=myocardial infarction.
        Reference: 1.Gerstein HC et al. Lancet. 2019 Jun 7. pii: S0140-6736(19)31149-3. doi: 10.1016/S0140-6736(19)31149-3. [Epub ahead of print]. 2.TBuse, J.B., Wexler, D.J., Tsapas, A. et al. 2019 update to: Management of  PP-DG-ZA-0332 Exp: 09/2023
        hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63, 221–228 (2020).
        https://doi.org/10.1007/s00125-019-05039-w 3.Trulicity ®  (dulaglutide once weekly) Trulicity ®  Professional Information , Eli Lilly and Company, Johannesburg, South Africa - 2020.  4.Trulicity ®  Instructions for use , Eli Lilly and
        Company, Johannesburg, South Africa - 2020
        S4
              Trulicity ® . Reg No. 51/21.13/0344 Dulaglutide 1,5 mg/ 0,5ml solution for injection.
        For more product information, please email us at: za_medinfo@lilly.com
        For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority
        Eli Lilly (S.A.) (Pty) Ltd. Reg. No. 1957/000371/07 1st Floor, Golden Oak House, Ballyoaks Office Park, 35 Ballyclare Drive, Bryanston, Johannesburg Tel: +27 (11) 510 9300
        © 2020 Eli Lilly and Company. All Rights Reserved.
   1   2   3   4   5   6   7